Latest Breaking News On - ஸ்விட்ச் மருத்துவ - Page 6 : comparemela.com

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress - In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2] - The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3] - Full results to be presented at the EULAR 2021 Virtual Congress - RINVOQ is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[2]

Clin rheumatolPhilip measeMudra kapoorPrnewswire abbvieExchange commissionJoseph healthEuropean commissionAbbvie deutschland gmbh coVirtual congressAmerican college of rheumatologyResults observedDisease activityLeeds enthesitis indexAmerican collegeRheumatology research divisionSwedish medical